Cullinan oncology reports inducement grants under nasdaq listing rule 5635(c)(4)

Cambridge, mass., jan. 03, 2023 (globe newswire) -- cullinan oncology, inc.  (nasdaq: cgem) (“cullinan”), a biopharmaceutical company focused on modality-agnostic targeted oncology for patients with cancer, today announced that the compensation committee of the company's board of directors granted stock option awards to purchase an aggregate of 37,000 shares of its common stock to three employees outside cullinan oncology, inc's 2021 stock option and incentive plan. the stock options were granted as an inducement material to the individuals entering into employment with cullinan, in accordance with nasdaq listing rule 5635(c)(4).
CGEM Ratings Summary
CGEM Quant Ranking